Journal of Clinical Lipidology

Article	Citations
A Single-Dose, Four-way-Crossover Comparative Bioavailability Study of Two Omega-3 Formulations under Fasting and Fed Conditions in Healthy Volunteers	133
Treatment Gap in Prevention of Myocardial Infarction in Rural New York State	129
News from NLA	117
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	94
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	66
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	62
Evidence of Direct Hepatic Secretion of Low density Lipoprotein (LDL) in Mice	61
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	56
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	52
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly-diagnosed metastatic pancreatic adenocarcinoma	49
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	48
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	47
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	45
Lipoprotein(a) concentrations across a global cross-sectional registry	44
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	42
Care of youth with lipid disorders: A brief provider survey	40
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	40
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	36
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	34
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	30
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	28
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	28
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	28
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	27
Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	27

Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19	25
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	24
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	24
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	23
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	22
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	22
Table of Contents	22
Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis	22
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	21
Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD	21
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	21
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	21
News from the NLA	20
The recognition and appreciation of Familial Hypercholesterolemia among Internal Medicine residents in the United States	20
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	19
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	19
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	19
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	19
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	18
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	18
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	17
Health Outcomes and Survival Among Patients with Severe Hypertriglyceridemia After Acute Pancreatitis	17
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	17
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	17
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	17
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk	17
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	15
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	15
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	15
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	15
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	15
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	14
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	14
Editorial Board	14
*An Unsolved Case: FH or Sitosterolemia?	13
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	13
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	13
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	13
Screening for Familial Hypercholesterolemia using Epic Secure Chat in Comparison to Epic Letter as Educational Outreach˄	12
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	12
Disparities Among Gender and Racial Groups in the Achievement of Optimal Lipid Levels in Patients Following Acute Coronary Syndrome	12
Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	12
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	12
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	11
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	11
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	11
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	11
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	11
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	11
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	11

Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	11
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	11
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	11
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	11
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	11
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	11
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	10
Enzyme Replacement Therapy in Cholesteryl Ester Storage Disease: A Case Report on Lysosomal Acid Lipase Deficiency Management	10
Extreme Lipoprotein (a) is a Cardiovascular Risk Equivalent in Heterozygous Familial Hypercholesterolemia	10
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) – Results of a US national survey	10
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	10
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	10
Hypertriglyceridemia induced Pancreatitis is associated with lower Inpatient Morbidity and Mortality compared to Biliary Pancreatitis	10
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	10
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	10
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	10
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	9
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	9
Community pharmacist impact of addressing statin use in patients with diabetes	9
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	9
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	9
Racial Disparities and Modifiable Risk Factors in Black Patients with Familial Hypercholesterolemia	9
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	9
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	9
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	9
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	9
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	9
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	8
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	8
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	8
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	8
Functional profiling of LDLR variants: Important evidence for variant classification	8
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	8
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	8
An Indian Adapted Mediterranean Diet: A feasibility study	8
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	8
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	8
Enhancing Lipoprotein(a) Association Studies: A Complementary Approach to Principal Component Analysis	7
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	7
From the editor: Heroes in a historic time	7
Spotlight on Abetalipoproteinemia and Related Hypobetalipoproteinemia Disorders: A Simplified Nomenclature and Clinical Guidelines. †	7
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	7
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	7
Early impact of 2018 AHA/ACC/Multisociety Cholesterol Guideline on lipid monitoring after statin initiation	7
Cardiovascular Mortality and Hospitalization Risk with LDL by CKD Stage in African-American and White US Veterans	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	7
Table of Contents	7
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	7
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	7
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	7
Dysbetalipoproteinamia: Implications for Pre-Conception, Pregnancy and Beyond	7
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	7
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	6
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	6
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	6
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	6
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	6
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	6
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	6
Hyperlipidemia and risk for preclampsia	6
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	6
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	6
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	6
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	6
From the editor: Lipidology resurgent as the pandemic wanes	6
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	6
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	5
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	5
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	5
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses	5
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	5
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5

Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	5
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial	5
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	5
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	5
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	5
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	5
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	5
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	5
From the editor: A compendium of lipidology progress	5
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	5
In memoriam: A tribute to Dr Scott M. Grundy	5
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	4
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	4
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	4
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	4
Moderate Alcohol Consumption and Lipoprotein Subfractions: A Systematic Review of Intervention and Observational Studies	4
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	4
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
Unveiling Compound Heterozygous Familial Hypercholesterolemia	4
Racial Variations in SGLT2 Inhibitor Prescriptions	4
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	4
Neurodegeneration in familial chylomicronemia syndrome	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	4
Editorial Board	4
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	4
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	4
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	4
Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2	4
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	4
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	4
†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates	4
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	4
Dedicated training in obesity management: A pathway to better physician practice	4
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence	4
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	4
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	4
Discontinuation of lipid-modifying agents and failure to achieve target LDL cholesterol levels across cardiovascular risk groups	4
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	4
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	4
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	4
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	4
Identification of High Cardiovascular Disease Risk Individuals in an Underserved Patient Population Clinic	4
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	4
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia	3
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	3
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	3
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center	3
A case of lipoprotein glomerulopathy due to the pathogenic APOE Las Vegas variant c.509C > A: p. (Ala170Asp)	3
Adult onset very long chain acyl-CoA dehydrogenase deficiency: A case report	3
Statin therapy for primary prevention in women: What is the role for coronary artery calcium?	3
Eicosapentaenoic Acid Reverses Endothelial Dysfunction following Exposure to the Cytokine IL-6 in Contrast to Docosahexaenoic and Arachidonic Acids	3
Impact of conducting a genetic study on the management of familial hypercholesterolemia	3
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.	3
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study	3
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	3
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	3
Improving adherence with lipid-lowering agents	3
Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series	3
Suboptimal response to monoclonal antibodies to subtilisin/kexin type 9: A step towards personalizing approach to lipid-modifying therapy	3
†Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies	3
Acknowledgement of Referees	3
Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia	3
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis	3
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation	3
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels	3
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	3
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	3
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients	3
Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy	3
Assessing LDL-C goal attainment in secondary prevention of atherosclerotic cardiovascular disease: Insights from the LAI-LCARE survey in India	3
Assessing omega-3 fatty acids–critically weighing options and relevance	3
Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue	3
Case Report - Lysosomal Acid Lipase Deficiency - A Rare Cardiometabolic Disease and a NAFLD Mimic	3
Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System	3
Forty year follow-up of three patients with complete absence of apolipoprotein B-containing lipoproteins	2
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?	2
Trends and experience with lipoprotein(a) testing in a large academic medical center	2
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model	2
LpX and LpZ associated hypercholesterolemia in a patient with primary sclerosing cholangitis – A case report	2
Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis	2
From the editor: Coyotes on the lawn	2
Impact of PCSK9 monoclonal antibody inhibitors on Lp(a) reduction in African Americans with elevated Lp(a)	2
Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels	2
Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals	2
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran	2
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia	2
Outcomes of hyperglycemic emergencies among African Americans compared to Caucasians: A large-scale nationwide analysis	2
Impact of value-based comprehensive medication management on statin prescribing in patients with type 2 diabetes mellitus	2
Unfavorably altered lipid profile in women with primary ovarian insufficiency	2